Retina

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.

Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.

A maternal high-fat diet can negatively affect the retinal structure in mice.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Why AI-driven functional imaging could change how clinicians assess and treat retinal disease

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

Andy Chang and Mikhail Boukhny of BVI Medical discuss the company's new Experience Hub in Sant Cugat, Spain, a hands-on training facility built to gather surgeon feedback ahead of the Virtuoso platform's European launch.

Utilize oral agents, diet and glucose monitoring systems when acting to preserve vision

New pathways are reshaping the management of retinal disease

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

The novel dual-port cutter, designed for use with the Stellaris Elite platform, offers increased flow rate and reduced cutter vibration.

Ultra-widefield imaging reveals early retinal risk in paediatric patients.

Professor Alió reflects on a new comprehensive volume dedicated to aging in ophthalmology

Temporal optical coherence tomography modelling may improve longitudinal disease tracking.

The dual-function phaco-vitrectomy platform is cleared for European commercialization, with launch targeted for Q3 2026.

Prof. Sobha Sivaprasad discusses why GA's multistage nature demands a broader therapeutic approach—and what evidence will shape clinical decision-making.

Prof. Anat Loewenstein questioned whether treat-and-extend will remain the preferred strategy as longer-acting therapies emerge.

Andrew G. Lee, MD, presents the “no” perspective on whether GLP-1 agonists cause non-arteritic anterior ischemic optic neuropathy, arguing that current evidence shows association but not proven causation.